2026-01-12 - Analysis Report
# Financial Report - TG Therapeutics Inc (TGTX)

## Company Overview
Company Name = TG Therapeutics Inc, a biopharmaceutical company.

## Return Rate Comparison
| Ticker | Cumulative Return |
|--------|------------------|
| TGTX   | 64.40%           |
| VOO    | 94.03%           |

Divergence (rate) = -30.63% (rate Vs rate_vs)
Divergence (max: 355.70, min: -91.40, current: -29.60, relative divergence: 13.80%)

## Alpha, Beta Analysis
| Year   | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|--------|---------|-------|---------|--------|--------|
| 2016-2018 | -53.0% | 71.9% | -56.0% | 1.8    | 0.7B   |
| 2017-2019 | 71.0%  | 71.9% | 54.0%  | 1.8    | 1.8B   |
| 2018-2020 | 332.0% | 71.9% | 311.0% | 1.6    | 8.3B   |
| 2019-2021 | 130.0% | 66.3% | 86.0%  | 1.6    | 3.0B   |
| 2020-2022 | -86.0% | 90.0% | -84.0% | 1.9    | 1.9B   |
| 2021-2023 | -315.0% | 89.7% | -316.0%| 2.4    | 2.7B   |
| 2022-2024 | 57.0%  | 76.8% | 38.0%  | 2.3    | 4.8B   |
| 2023-2025 | 67.0%  | 76.8% | 4.0%   | 1.1    | 4.7B   |

## Recent Stock Price Fluctuations
- Close: $28.47
- Last-market: {'price': 28.47, 'previousClose': 30.5, 'change': -6.66}
- 5-day SMA: $29.72
- 20-day SMA: $30.46
- 60-day SMA: $31.87

## RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return Analysis
- MRI: 0.70 (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
- RSI: 40.94
- PPO: -0.23
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: -1.70 (-): worsening
- 7-day Rank change: 1 (+): rank up
- 7-day Dynamic Expected Return change: -10.50 (-): worsening
- Expected Return (%): -86.60%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

## News and Significant Events
- [2026-01-09] TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next - TechStock² (news.google.com)
- [2025-10-31] TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance (news.google.com)
- [2025-12-30] TG Therapeutics: What Wall Street Isn't Telling You (NASDAQ:TGTX) - Seeking Alpha (news.google.com)
- [2025-11-03] The Earnings Caveat That Sent This Hot Biotech Diving - Investor's Business Daily (news.google.com)
- [2025-12-19] Is the Options Market Predicting a Spike in TG Therapeutics Stock? - Zacks Investment Research (news.google.com)
- [2026-01-11] BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Raises Target Price to $15 - 富途牛牛 (news.google.com)

## Analyst Opinions
- Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.67 (~Buy)
- Opinions: 7
- Target Price (avg/high/low): 44.57 / 60.00 / 15.00

## Recent Earnings Analysis
| Date    | EPS | Revenue |
|---------|-----|---------|
| 2025-11-05 | 2.69 | $0.16B  |
| 2025-08-08 | 0.19 | $0.14B  |
| 2025-05-09 | 0.03 | $0.12B  |
| 2024-11-07 | 0.03 | $0.08B  |
| 2025-11-05 | 0.03 | $0.08B  |

Revenue and Profitability:
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.16B | 82.63% |
| 2025-06-30 | $0.14B | 86.58% |
| 2025-03-31 | $0.12B | 87.14% |
| 2024-12-31 | $0.11B | 85.77% |
| 2024-09-30 | $0.08B | 88.86% |

Capital and Profitability:
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $0.61B | 64.37% |
| 2025-06-30 | $0.28B | 10.20% |
| 2025-03-31 | $0.24B | 2.13% |
| 2024-12-31 | $0.22B | 10.49% |
| 2024-09-30 | $0.19B | 2.02% |

## Comprehensive Analysis (Summary)
- Recent stock price fluctuations reflect a sharp decline with a 20-day SMA of $30.46.
- RSI and PPO indicators are at 40.94 and -0.23 respectively, indicating potential buy signal.
- Expected return is at -86.60%, indicating a potential long-term excess return compared to S&P 500.
- Analyst consensus is at Buy with a mean of 1.67 and 7 opinions.
- Recent earnings analysis shows a significant EPS in 2025-11-05 with a revenue of $0.16B.
- Financial information shows a revenue of $0.16B in 2025-09-30 with a profit margin of 82.63%.
- Capital and profitability information shows an equity of $0.61B in 2025-09-30 with an ROE of 64.37%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.